newsfilter
← Latest News
GlobeNewswire·

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and recovery